- Home
- NAAS vs OTLK Comparison
NAAS vs OTLK Comparison
Compare NAAS & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAAS | OTLK |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.4M | 29.2M |
| IPO Year | 2017 | 2016 |
Fundamental Metrics
Financial Performance| Metric | NAAS | OTLK |
|---|---|---|
| Price | $2.48 | $0.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 4.3K | ★ 4.4M |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,146,123.00 |
| Revenue This Year | $378.49 | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.16 |
| 52 Week High | $4.54 | $3.39 |
Technical Indicators
Market Signals| Indicator | NAAS | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 49.33 | 46.18 |
| Support Level | $2.23 | $0.17 |
| Resistance Level | $2.70 | $0.29 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 33.12 | 84.11 |
Price Performance
Historical ComparisonAbout NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators, a wide range of offline services that simplify the daily operations of charging station operators, and non-charging services such as food and beverage services to station operators.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.